Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It
This article was originally published in The Tan Sheet
Executive Summary
Novartis will enter the U.S. over-the-counter analgesics market with Excedrin as part of the purchase of Bristol-Myers Squibb's OTC portfolio